Eisai/Biogen Get Some Lecanemab Exposure

Lecanemab, the antiamyloid antibody being jointly developed by Eisai and Biogen, grabbed the clinical trial world with a fresh look at extension data and news of its inclusion in an important treatment trial for genetically driven Alzheimer’s disease.
Source: Drug Industry Daily